May 30, 2023
Research work carried out at Genethon rewarded at the 26th edition of the ASGCT
February 24, 2023
Chronic septic granulomatosis: biomarkers predict the efficacy of gene therapy
February 7, 2023
“We made important achievements in 2022 but we still face key challenges in the year ahead”
January 10, 2023
Genethon Launches Pivotal Clinical Trial of Gene Therapy for Crigler-Najjar Syndrome, a Rare Liver Disease
January 6, 2023
Genethon wishes you a happy new year 2023!
In 2023, we will not give up and continue the fight against rare diseases
(read more)December 14, 2022
Publication: Genethon helps clarify a molecular mechanism of mitochondrial malfunction in Duchenne muscular dystrophy
Several laboratories, including Généthon, have begun gene therapy clinical trials for Duchenne muscular dystrophy. Research must be conducted, however, to improve the therapeutic benefit of future treatments for this rare genetic disease.
(read more)November 21, 2022
Téléthon 2022: Benjamin, a hope for families thanks to clinical trials
Suffering from Duchenne muscular dystrophy, a neuromuscular disease that is now incurable, Benjamin, 10, is one of the ambassadors of Téléthon 2022. Genethon recently launched a gene therapy trial for this disease.
(read more)Telethon 2022: for Lucie, “a real opportunity, thanks to advances in research”
Lucie has spinal muscular atrophy. A year ago, she was able to benefit from a gene therapy treatment based on technologies developed at Genethon. Lucie and her parents will be ambassadors of the 2022 Telethon.
(read more)October 5, 2022
Publication: Genethon helps identify two vectors optimized for muscles via a European H2020 program
Making gene therapy vectors more specific is a major challenge in gene therapy. Edith Renaud-Gabardos, under the direction of Ana Buj-Bello, an Inserm Research Director, and several other Genethon collaborators, co-authored a publication in Science Advances demonstrating the optimized effectiveness of two capsids for muscle… (read more)
September 26, 2022
First Patient Dosed in Phase 1/2 Clinical Trial in Europe of Gene Therapy for LGMD-R9
Study to treat FKRP-related limb-girdle muscular dystrophy type 2I/R9 represents 30 years of research and is being conducted by Genethon spinout Atamyo Therapeutics.
(read more)July 20, 2022
The Genethon platforms obtain ISO 9001 certification
As of July 8, 2022, the Imaging-Cytometry, Preclinical Evaluation and Technological Development platforms have been officially ISO 9001 certified. An additional guarantee of the quality of the activities of these platforms.
(read more)July 15, 2022
Anne Galy receives the WAS Foundation Callahan Award for her work on Wiskott-Aldrich syndrome
The WAS Foundation awarded the Callahan Prize for outstanding service to Anne Galy, head of the Immunology and biotherapies team. She has worked for more than 20 years on Wiskott-Aldrich syndrome, a severe immune deficiency of genetic origin.
(read more)July 8, 2022
Sickle-cell anemia: a project involving the Gene editing team has just secured European funding
The “EDITSCD” project, that aims to improve gene editing strategies for sickle-cell anemia, this hereditary disease of the red blood cells, has just been selected by the European Union. It will involve a dozen or so research laboratories in Europe, among then the Gene editing team (Inserm UMR 951) headed by Mario Amendola at… (read more)
February 28, 2022
Gene Therapies Continue to Emerge as Effective Treatments for Rare Diseases, But Complex Challenges Remain
To mark International Rare Disease Day, Genethon identifies the most urgent priorities in overcoming these obstacles.
(read more)February 15, 2022
Five post-doctoral positions open at Genethon, a leader in gene therapy for rare diseases
A pioneer and leader in gene therapy for rare disease, Genethon, a non-profit organization, recruits 5 post-doctoral fellow to develop research projects the Inserm-Genethon-UEVE Integrare unit.
(read more)